key: cord-0707117-8d5stixw authors: Dinoto, E.; Ferlito, F.; La Marca, M.A.; Mirabella, D.; Bajardi, G.; Pecoraro, F. title: Staged acute mesenteric and peripheral ischemia treatment in COVID-19 patient: Case report date: 2021-06-09 journal: Int J Surg Case Rep DOI: 10.1016/j.ijscr.2021.106105 sha: c55e10ac30a606a901478270cf26040322dde6fd doc_id: 707117 cord_uid: 8d5stixw INTRODUCTION: COVID-19 is an infectious disease that has been associated not only with respiratory complications. The COVID-19 disease includes, also damage to other organ systems as well as coagulopathy. The present report describes a case of COVID-19 presenting with acute mesenteric ischemia (AMI) and subsequent acute limb ischemia (ALI). PRESENTATION OF CASE: An 84-years old hospitalized female patient presenting diabetes and recent COVID-19 reported acute onset of abdominal pain and typical findings of AMI. The CT-angiography confirmed the AMI secondary to a superior mesenteric artery (SMA) occlusion. The patient was managed through an endovascular approach using a SMA mechanical thrombectomy and stenting with a good result. DISCUSSION: Treatment of this life-threatening condition includes surgical resection of the necrotic bowel, restoration of blood flow to the ischemic intestine and supportive measure - gastrointestinal decompression, fluid resuscitation, hemodynamic support. Endovascular management of AMI is preferred over the standard surgical approach due to a reduced mortality and morbidity rates. Imaging findings of intestinal necrosis, however, represent an indication for AMI surgical treatment with explorative laparotomy. Different endovascular solutions have been employed to address AMI including mechanical thrombectomy, local thrombolysis, and PTA-stenting. CONCLUSION: COVID-19 clinical presentation can be atypical, including gastrointestinal symptoms. If a first embolic event occurs, an aggressive anticoagulation treatment could be inefficient to reduce the risk of subsequent embolization events. The limited life expectancy of such revascularization procedures should orientate towards less invasive treatments. Coronavirus disease 19 (COVID-19) pandemic is worldwide affecting more than 150 million people including more than 3 million deaths. 1 has been increasingly associated with thromboembolic complications in both arterial and venous districts. Hyperinflammation, platelet activation, endothelial dysfunction, and stasis have been advocated as predisponent to thrombotic complications. 2 Acute ischemic manifestations in COVID-19 patients are frequently reported, especially in the peripheral district. 3 A single patient presenting consecutive acute mesenteric ischemia (AMI) and subsequent acute limb ischemia (ALI) is reported. This work has been written in accordance with the SCARE criteria. 4 Case Report. An 84-year-old female with hypertension, diabetes mellitus, severe renal failure (Glomerular filtration rate -GFR -44 ml/min) was referred to our hospital for fever and dyspnea. Medical history reported gastric ulcer disease with hematemesis and angioplasty for diabetic peripheral artery disease in pharmacological treatment with regular anti-platelet therapy (Cardioaspirin -Bayer, 100 mg/day). No coronary artery disease or cardiac arrhythmias were reported. At admission, her physical examination revealed a sinusal heart rate of 90 bpm, blood pressure of 105/70 mmHg, fever (37.5 °C), respiratory rate of 20 breaths/min, and oxygen saturation of 89%, abdomen's soft and non-tender in the absence of pain. The pulmonary CT scan showed the typical finding of COVID 19 infection and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with the typical interstitial pneumonia infection Abdominal CT-angiography showed superior mesenteric artery (SMA) origin stenosis and occlusion after 2 cm from the origin (Fig. 2) ; CT findings of AMI at an early stage were reported including the absence of bowel mural enhancement in the proximal part of the ileum. No intestinal necrosis findings were reported (Fig. 3) . A surgical attempt with SMA thrombectomy was excluded due to the high surgical risk mainly related to respiratory impairment and on this basis, an endovascular approach was chosen. The treatment consisted of percutaneous trans-brachial access simultaneous mechanical thrombectomy using a 6F catheter Export AP Aspiration Catheter (Medtronic Minneapolis, MN) and proximal SMA balloon-expandable uncovered stenting (6x20 mm Isthmus, CID SpA, IT) with SMA patency restoration (Fig. 5 ). In brief, the SMA was cannulated using a reverse-curve catheter and a hydrophilic 0·035-inch guidewire, which is placed into the ileocolic branch of the SMA. The wire is then replaced with a stiffer, Amplatz (Boston Scientific -Natick, Massachusetts) or Rosen (Cook Inc -Bloomington, IN) to achieve stability and a 6-Fr /45 cm Destination (Terumo Corporation, Tokyo, Japan) introducer placed proximal to the embolus in the SMA. Inside the long introducer, a 6-Fr guiding catheter is positioned into the clot, which is aspirated with a 20-ml syringe while the introducer is withdrawn. In presence of thrombus, usually, stenting is contraindicated but it can be used in presence of calcification or to preserve primary patency. At 24 hours from the index operation, the CT-angiography confirmed SMA patency with a nonsignificant residual thrombus on the artery wall and maintenance of SMA distal flow. Clinical and laboratory findings were suggestive for AMI regression due to abdominal pain The right ALI was managed under local anesthesia by hybrid surgical transfemoral thrombectomy and distal superficial femoral artery stenting due to a residual dissection. At 24-hours from the second procedure the leg appeared normothermic with a good popliteal pulse, the DUS confirmed patent femoropopliteal arteries. At the same time, the patient showed a significant decline of respiratory function requiring intensive care management and death on the 5 th postoperative day from the second intervention due to respiratory acute failure. The usual clinical presentation of COVID-19 is fever and respiratory symptoms. Abdominal symptoms are also a common finding in COVID-19 patients and have been reported in 16% of cases. 5 Less frequently COVID-19 patients present with arterial or venous occlusion in different districts including AMI and ALI. 6 Vaccination modeling for safe surgeries and identification of timing of surgery in COVID-19 patients are currently under investigation. 7, 8 Treatment of this life-threatening condition includes surgical resection of the necrotic bowel, restoration of blood flow to the ischemic intestine and supportive measure -gastrointestinal decompression, fluid resuscitation, hemodynamic support. 9 Endovascular management of AMI is preferred over the standard surgical approach due to a reduced mortality and morbidity rates. 10 Imaging findings of intestinal necrosis, however, represent an indication for AMI surgical treatment with explorative laparotomy. 11 Different endovascular solutions have been employed to address Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note. Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways, should be listed as contributors. J o u r n a l P r e -p r o o f Ettore Dinoto: study concept, design, data collection, data analysis, interpretation, writing the paper, final approval of the version to be submitted, guarantor. Felice Pecoraro: study concept, design, data collection, data analysis, interpretation, writing the paper, final approval of the version to be submitted. Ferlito Francesca: study concept, design, data collection, data analysis, interpretation, final approval of the version to be submitted. La Marca Manfredi: study concept, design, data collection, final approval of the version to be submitted. Mirabella Domenico: study concept, design, data collection, final approval of the version to be submitted. Guido Bajardi: study concept, design, data collection, data analysis, interpretation, final approval of the version to be submitted. In accordance with the Declaration of Helsinki 2013, the Editors of IJS Case Reports require that reports that are 'First in Man' studies should be registered prospectively and failing that retrospectively. There are many places to register your First in Man case report: World Health Organization website COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines Abdominal imaging findings in patients with SARS-CoV-2 infection: a scoping review China: A Descriptive, Cross-Sectional, Multicenter Study Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study COVID-19 and acute mesenteric ischemia: A review of literature Extra-anatomic iliac to superior mesenteric artery bypass after bridge endovascular treatment for chronic mesenteric ischemia. A case report Endovascular and open surgery for acute occlusion of the superior mesenteric artery Endovascular therapeutic approaches for acute superior mesenteric artery occlusion Primary percutaneous aspiration and thrombolysis for the treatment of acute embolic superior mesenteric artery occlusion Managing Peripheral Artery Disease in Diabetic Patients: A Questionnaire Survey from Vascular Centers of the Mediterranean Federation for the Advancing of Vascular Surgery (MeFAVS) Single staged hybrid approach for multilevel aortic-iliac-femoral-popliteal disease Superior Mesenteric Arterial and Venous Thrombosis in COVID-19 The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories, then this should be stated. All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Please state any sources of funding for your research All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state. Research studies involving patients require ethical approval. Please state whether approval or exemption has been given, name the relevant ethics committee and the state the reference number for their judgement. Please give a statement regarding ethnical approval that will be included in the publication of your article, if the study is exempt from ethnical approval in your institution please state this. Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request". J o u r n a l P r e -p r o o f